During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...